AC
CRDF icon

AlphaCore Capital’s Cardiff Oncology CRDF Stock Holding History

AlphaCore Capital’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$141K Buy
108,493
+67
+0.1% +$106 ﹤0.01% 1163
2026
Q1 		$176K Sell
108,426
-6,000
-5% -$12.3K ﹤0.01% 861
2025
Q4 		$322K Buy
114,426
+4,500
+4% +$10.4K 0.01% 777
2025
Q3 		$226K Buy
109,926
+8,351
+8% +$23.1K 0.01% 666
2025
Q2 		$320K Buy
+101,575
New +$310K 0.01% 470

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AlphaCore Capital's CRDF Position: Q2 2026 in Review

AlphaCore Capital increased its Cardiff Oncology (CRDF) stake by 0.06% in Q2 2026, buying an estimated $106 and bringing the position to 108,493 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #1163.

AlphaCore Capital first reported a position in CRDF in Q2 2025 and has held it in 5 quarters since. The position peaked at $322K in Q4 2025. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • AlphaCore Capital held 108,493 shares of Cardiff Oncology worth $141K as of Q2 2026.
  • AlphaCore Capital bought 67 Cardiff Oncology shares in Q2 2026, an estimated $106.
  • Cardiff Oncology made up ﹤0.01% of AlphaCore Capital's portfolio in Q2 2026, its #1163 holding.
  • AlphaCore Capital first reported a position in Cardiff Oncology in Q2 2025 and has held it in 5 quarters since.
  • AlphaCore Capital's Cardiff Oncology position peaked at $322K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.